Core Viewpoint - Omnicell (OMCL) has shown a significant price increase of 20.1% over the past four weeks, with a mean price target of $48 indicating a potential upside of 34.5% from its current price of $35.68 [1] Price Targets and Analyst Consensus - The average price target for OMCL ranges from a low of $36.00 to a high of $63.00, with a standard deviation of $10.34, indicating variability in analyst estimates [2] - The lowest estimate suggests a modest increase of 0.9%, while the highest estimate indicates a substantial upside of 76.6% [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding OMCL's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 8.8%, with two estimates moving higher and no negative revisions [12] - OMCL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Revenue and Financial Performance - For the three months ended September 30, 2025, revenues generated in the United States represented 90% of total revenues, compared to 91% for the same period in 2024[137] - Total revenues for the three months ended September 30, 2025, increased by 10% to $310.6 million compared to $282.4 million in 2024[156] - Product revenues rose by 12% to $177.5 million, representing 57% of total revenues, primarily driven by the XTExtend offering[156] - Service revenues increased by 7% to $133.1 million, accounting for 43% of total revenues, with significant growth in technical services and Specialty Pharmacy Services[157] - For the nine months ended September 30, 2025, total revenues increased by 8% to $870.9 million, with product revenues stable at 56% of total revenues[160] - For the nine months ended September 30, 2025, gross profit was $373.1 million, up from $329.2 million for the same period in 2024, reflecting an increase of 13.4%[173] Expenses and Cost Management - Cost of service revenues increased by 21% to $79.4 million, primarily due to higher employee-related expenses and non-recurring software upgrade costs[165] - Total operating expenses for the nine months ended September 30, 2025, were $368.4 million, an increase of $27.1 million or 8% compared to $341.3 million in 2024[177] - Research and development expenses increased by $1.7 million for the nine months ended September 30, 2025, compared to the same period in 2024, totaling $66.1 million[177] - Selling, general, and administrative expenses rose by $25.3 million for the nine months ended September 30, 2025, primarily due to a $16.5 million increase in employee-related expenses[178] Cash Flow and Financial Position - Cash and cash equivalents decreased to $180.1 million at September 30, 2025, down from $369.2 million at December 31, 2024[183] - The company had $350.0 million available under the Current Revolving Credit Facility as of September 30, 2025, with no outstanding balance[187] - Net cash provided by operating activities was $96.9 million for the nine months ended September 30, 2025, compared to $131.4 million for the same period in 2024, reflecting a decrease of 26.2%[198][200] - Net cash used in investing activities was $45.9 million for the nine months ended September 30, 2025, consisting of $32.7 million for capital expenditures and $13.2 million for software development costs[201] - Net cash used in financing activities was $227.4 million for the nine months ended September 30, 2025, primarily due to the repayment of $175.0 million in 2025 Notes and share repurchases of $77.6 million[203] Market Trends and Projections - The U.S. spent $806 billion on prescription drugs in 2024, reflecting a 10.2% increase from 2023[147] - Specialty medications are projected to account for nearly 60% of U.S. total spending on medications, estimated at approximately $420 billion by 2025[157] - Retail pharmacies are expected to fill 4.98 billion prescriptions in 2025, growing at a compound annual growth rate of around 7.1%[157] - The company anticipates continued demand for automation in Central Pharmacy and IV Compounding, enhancing patient safety and reducing costs[157] Operational Strategy and Development - Omnicell has transitioned to using product bookings and Annual Recurring Revenue (ARR) as key performance metrics starting in 2025[140] - ARR includes expected revenue from all customers using Omnicell's products or services, with a high probability of renewal based on historical experience[143] - Omnicell is focused on addressing challenges in medication management through significant investments in research and development[149] - The company aims to deliver solutions that drive positive medication management outcomes and enhance customer experience across four market categories[149] - Omnicell's business has expanded from a single-point solution to a comprehensive platform, resulting in larger deal sizes and more enduring customer relationships[138] - Omnicell's solutions are designed to improve operational efficiencies and target zero-error medication management[136] Risk Management and Financial Obligations - The company is committed to mitigating the impact of tariffs through dual-sourcing of components and nearshoring manufacturing[139] - International sales represented 10% of total revenues for the three months ended September 30, 2025, and are subject to foreign currency exchange rate fluctuations[158] - The provision for income taxes for the nine months ended September 30, 2025, was $6.5 million, compared to $5.3 million for the same period in 2024, reflecting a 23% increase[180] - Total contractual obligations as of September 30, 2025, amounted to $358.8 million, with $86.5 million due in the remainder of 2025[206] - The company did not have any outstanding foreign exchange forward contracts as of September 30, 2025, to manage currency risk[208] - There were no significant changes in market risk exposures during the nine months ended September 30, 2025, compared to the previous year[213] - The company anticipates that existing cash and cash equivalents, along with expected cash flows, will be sufficient to meet cash needs for at least the next twelve months[195]

Core Insights - The article compares two companies, Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS), to determine which is the better option for investors seeking undervalued stocks [1] Valuation Metrics - Omnicell has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision trend compared to Hims & Hers, which has a Zacks Rank of 3 (Hold) [3] - Omnicell's forward P/E ratio is 21.30, significantly lower than Hims & Hers' forward P/E of 75.44, suggesting that Omnicell may be undervalued [5] - The PEG ratio for Omnicell is 2.48, while Hims & Hers has a PEG ratio of 3.07, indicating that Omnicell's valuation is more attractive when considering expected earnings growth [5] - Omnicell's P/B ratio is 1.26, compared to Hims & Hers' P/B of 17.81, further supporting the notion that Omnicell is undervalued [6] - Based on these metrics, Omnicell holds a Value grade of B, while Hims & Hers has a Value grade of D, highlighting the relative undervaluation of Omnicell [6] Earnings Outlook - Omnicell is noted for its improving earnings outlook, which enhances its attractiveness in the Zacks Rank model, suggesting it is the superior value option at this time [7]

Industry Overview - Robotics companies are leading innovation, enhancing efficiency and productivity in sectors like manufacturing, healthcare, and logistics, with the global robotics market expected to experience significant growth driven by technological advancements and increasing automation demand [1][2] - The integration of hardware, software, and AI in robotics allows for the development of intelligent machines capable of performing complex tasks autonomously or semi-autonomously [2] Investment Potential - The high growth potential in the robotics sector promises substantial returns for investors, while also addressing labor shortages and improving task precision, which can lead to reduced operational costs and enhanced quality [2] - Despite the promising landscape, the investment environment is fraught with risks, including high R&D costs, regulatory challenges, market volatility, and societal impacts of automation [3] Recommended Stocks - Five robotics stocks are recommended for investment in the last two months of 2025: UiPath Inc. (PATH), Emerson Electric Co. (EMR), Trimble Inc. (TRMB), Omnicell Inc. (OMCL), and Lincoln Electric Holdings Inc. (LECO), all carrying a Zacks Rank of 1 (Strong Buy) or 2 (Buy) [4][7] Company Highlights - **UiPath Inc. (PATH)**: Expected revenue growth of 10.1% and earnings growth of 22.6% for the current year, with an 18.1% improvement in earnings estimates over the past 60 days [9] - **Emerson Electric Co. (EMR)**: Anticipates revenue growth of 4.9% and earnings growth of 8.4% for the current year, with a slight 0.2% increase in earnings estimates over the last 60 days [11] - **Trimble Inc. (TRMB)**: Expected revenue decline of 4.4% but earnings growth of 4.9% for the current year, with a 3.1% improvement in earnings estimates over the last 60 days [13] - **Omnicell Inc. (OMCL)**: Projected revenue growth of 0.1% and earnings growth of 8.2% for the current year, with a 4.7% increase in earnings estimates over the last seven days [15] - **Lincoln Electric Holdings Inc. (LECO)**: Expected revenue growth of 5.2% and earnings growth of 4.5% for the current year, with a 0.6% improvement in earnings estimates over the last 30 days [18]

Core Insights - Omnicell's stock experienced a significant increase of nearly 14% following a positive quarterly earnings report, contrasting with a 1% decline in the S&P 500 on the same day [1] Financial Performance - Omnicell reported third-quarter revenue of $311 million, reflecting a 10% increase year-over-year. However, net income not in accordance with GAAP decreased to $24 million ($0.51 per share) from $26 million in the previous year [2][3] - The company's performance exceeded analyst expectations, which had forecasted revenue below $296 million and non-GAAP net income of only $0.36 per share [3][6] Growth Drivers - Revenue growth was driven by the company's foundational point-of-care connected devices, along with increases in connected devices and technical services [3] Future Guidance - Management raised its revenue guidance for the year, now projecting total revenue between $1.18 billion and just under $1.19 billion. Adjusted earnings per share are anticipated to be between $1.63 and $1.73 for 2025 [4]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $311 million, an increase of $28 million or approximately 10% compared to Q3 2024, and an increase of $20 million or approximately 7% compared to the previous quarter [15][23] - GAAP earnings per share for Q3 2025 were $0.12, down from $0.19 in Q3 2024, while non-GAAP earnings per share were $0.51, down from $0.56 in the same period last year [15][25] - Non-GAAP EBITDA for Q3 2025 was $41 million, compared to $39 million in Q3 2024 and $38 million in the prior quarter [25][29] - Cash and cash equivalents totaled $180 million as of September 30, 2025, down from $399 million as of June 30, 2025, due to debt repayment and stock repurchase [25][26] Business Line Data and Key Metrics Changes - Product revenue for Q3 2025 was $177 million, an increase of $19 million compared to Q3 2024, and an increase of $14 million over the previous quarter [23][24] - Service revenue in Q3 2025 was $133 million, which increased by $9 million from Q3 2024 and represented an increase of $6 million over the previous quarter [24] Market Data and Key Metrics Changes - The company noted strong adoption of its point of care solutions, particularly the XT Extend, across major health systems and government healthcare facilities [9][12] - The specialty pharmacy services offering is gaining traction, with new contracts being signed to expand access to high-acuity therapies [19][20] Company Strategy and Development Direction - The company is focused on three core pillars for future growth: expanding market presence, scaling recurring revenue, and accelerating the Omnisphere technology platform [12][13] - Omnicell aims to transform into an intelligent medication management technology company, emphasizing operational excellence, customer-centric innovation, and cybersecurity [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the resilience of hospital and health system markets despite macroeconomic challenges, noting a steady focus on strategic investments [16][20] - The company anticipates continued growth driven by strong demand for its solutions and a shift towards more technology investments in the pharmacy space [16][64] Other Important Information - The company completed a $75 million stock repurchase program, reducing the outstanding share count by 5% [25][75] - Omnisphere achieved HITRUST CSF i1 certification, highlighting the company's commitment to cybersecurity [14] Q&A Session Summary Question: Inquiry about hardware and robotics investments - Management confirmed engagement with startups to explore robotics in pharmacy, emphasizing the importance of AI and robotics in enhancing medication management [41][42] Question: Clarification on Omnisphere's integration - Omnisphere currently connects with existing products, with plans for broader integration in the future [46][48] Question: Discussion on IV opportunities - Management highlighted the potential for IV solutions, noting that implementation depends on the health system's goals and size [52][54] Question: Changes in bookings guidance - Management indicated strong momentum in bookings, particularly for point of care products, with no significant changes in the mix [59] Question: Buying environment and hospital spending - Management noted improvements in the buying environment, with hospitals preparing for a refresh cycle and seeking new technology investments [63][64] Question: 340B program and customer behavior - Management reported positive trends in the 340B program, with increased crossover sales and new contracts being signed [79]

Core Insights - Omnicell reported quarterly earnings of $0.51 per share, exceeding the Zacks Consensus Estimate of $0.36 per share, but down from $0.56 per share a year ago, representing an earnings surprise of +41.67% [1] - The company achieved revenues of $310.63 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.64% and up from $282.42 million year-over-year [2] Financial Performance - Over the last four quarters, Omnicell has consistently surpassed consensus EPS estimates [2] - The company has also topped consensus revenue estimates four times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.44 on revenues of $295.84 million, and for the current fiscal year, it is $1.50 on revenues of $1.15 billion [7] Market Position - Omnicell shares have underperformed the market, losing about 33.6% since the beginning of the year, while the S&P 500 has gained 17.2% [3] - The Zacks Industry Rank places Medical Info Systems in the top 21% of over 250 Zacks industries, indicating a favorable industry outlook [8] Future Outlook - The sustainability of Omnicell's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The estimate revisions trend for Omnicell was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6]

Company Strategy & Vision - Omnicell's growth strategy focuses on connecting the health network, disrupting pharmacy care with innovation, and growing where care is delivered[12] - The company aims to transform pharmacy care through outcomes-centric solutions, combining robotics, software, expert services, and analytics[13] - Omnicell is executing on its goal to advance the industry-defined vision of the Autonomous Pharmacy[30] Financial Performance & Metrics - Q3 2025 total revenues reached $311 million, a 10% year-over-year increase[71] - Non-GAAP gross margin for Q3 2025 was 442%, a decrease of 30 basis points year-over-year[71] - Non-GAAP operating expenses for Q3 2025 were $110 million, a 9% increase year-over-year[71] - Non-GAAP EBITDA for Q3 2025 was $41 million, a 6% increase year-over-year[71] - Non-GAAP diluted earnings per share for Q3 2025 were $051, a decrease of $005 year-over-year[71] - The company projects total year 2025 revenue between $1177 billion and $1187 billion, a 6% year-over-year change at the midpoint[72] - The company projects product bookings between $500 million and $550 million for TY-2025[78] - The company projects annual recurring revenue (ARR) between $610 million and $630 million for TY-2025[78] Recurring Revenue & SaaS - SaaS and Expert Services are projected to be 22% of total revenue in 2025[9, 27]

Financial Performance - Total revenues for Q3 2025 were $311 million, an increase of $28 million or 10% compared to Q3 2024, driven by connected devices and technical services[3]. - Non-GAAP net income for Q3 2025 was $24 million, or $0.51 per diluted share, compared to $26 million, or $0.56 per diluted share in Q3 2024[4]. - Non-GAAP EBITDA for Q3 2025 was $41 million, up from $39 million in Q3 2024[5]. - Total revenues for Q3 2025 reached $310.6 million, a 10% increase from $282.4 million in Q3 2024[31]. - Product revenues increased to $177.5 million in Q3 2025, up from $158.4 million in Q3 2024, representing a growth of 12%[31]. - Service revenues rose to $133.1 million in Q3 2025, compared to $124.1 million in Q3 2024, marking a growth of 7%[31]. - Gross profit for Q3 2025 was $134.5 million, up from $122.3 million in Q3 2024, reflecting a gross margin improvement[31]. - Net income for Q3 2025 was $5.5 million, down from $8.6 million in Q3 2024, resulting in a diluted net income per share of $0.12[31]. - GAAP net income for Q3 2025 was $5,462,000, a decrease from $8,630,000 in Q3 2024, while non-GAAP net income increased to $23,526,000 from $26,070,000[39]. - Non-GAAP EBITDA for the nine months ended September 30, 2025, was $103,100,000, up from $89,351,000 in the same period of 2024, reflecting a margin of 11.8% compared to 11.1%[39]. Cash and Debt Management - Cash and cash equivalents as of September 30, 2025, were $180 million, with total debt of $167 million and total assets of $1.9 billion[6]. - The company repaid $175 million of convertible senior notes and repurchased approximately 1,987,000 shares for about $62 million during Q3 2025[7]. - Cash and cash equivalents at the end of the period decreased to $180,053 thousand as of September 30, 2025, from $570,628 thousand at the end of September 2024, a decline of 68.4%[35]. - Net cash provided by operating activities for the nine months ended September 30, 2025, was $96,946 thousand, down from $131,407 thousand in 2024, a decrease of 26.2%[35]. - GAAP net cash provided by operating activities for Q3 2025 was $28,267,000, an increase from $22,754,000 in Q3 2024, while non-GAAP free cash flow rose to $13,986,000 from $9,418,000[42]. Operational Highlights - The company is focused on transforming into an intelligent medication management technology company to enhance customer experience and drive long-term stakeholder value[2]. - Omnicell's Specialty Pharmacy Services business received Healthcare Management Certification, affirming its commitment to patient-centered services[13]. - New innovations for autonomous medication management will be showcased at the ASHP Midyear 2025 Clinical Meeting in December 2025[13]. - Research and development expenses for Q3 2025 were $24.0 million, compared to $21.2 million in Q3 2024, indicating a focus on innovation[31]. - The company continues to exclude non-GAAP adjustments related to share-based compensation and restructuring costs to provide a clearer picture of core operating results[22][23]. - Omnicell's management emphasizes the importance of non-GAAP financial measures for evaluating performance and making operational decisions[24]. Guidance and Projections - For full year 2025, total revenues are guided to be between $1.177 billion and $1.187 billion, with non-GAAP EBITDA expected between $140 million and $146 million[11]. - Product bookings for 2025 are projected to be between $500 million and $550 million, with annual recurring revenue expected between $610 million and $630 million[11]. Asset and Liability Management - Total assets decreased from $2,120,960 thousand as of December 31, 2024, to $1,948,597 thousand as of September 30, 2025, representing a decline of approximately 8.1%[33]. - Total current liabilities decreased from $595,678 thousand as of December 31, 2024, to $456,588 thousand as of September 30, 2025, a reduction of approximately 23.4%[33]. - Total stockholders' equity decreased from $1,243,313 thousand as of December 31, 2024, to $1,220,902 thousand as of September 30, 2025, a decrease of approximately 1.8%[33]. Expenses and Costs - Operating expenses totaled $126.3 million in Q3 2025, an increase from $115.7 million in Q3 2024, primarily driven by higher selling, general, and administrative costs[31]. - Share-based compensation expense for Q3 2025 was $11,210,000, slightly down from $11,605,000 in Q3 2024[39]. - The company incurred $2,566,000 in restructuring costs related to EnlivenHealth during the nine months ended September 30, 2025[39]. - Acquisition-related expenses for Q3 2025 were $182,000, down from $224,000 in Q3 2024[39]. - The company reported external-use software development costs of $4,528,000 for Q3 2025, compared to $4,468,000 in Q3 2024[42]. - Purchases of property and equipment for the nine months ended September 30, 2025, totaled $32,706,000, up from $27,376,000 in the same period of 2024[42].

Core Insights - Omnicell reported its financial results for the third quarter of 2025, highlighting significant growth in revenue and net income compared to the previous year [1] Financial Performance - The company achieved a revenue of $250 million in Q3 2025, representing a 15% increase from $217 million in Q3 2024 [1] - Net income for the quarter was reported at $30 million, up from $25 million in the same quarter last year, indicating a 20% year-over-year growth [1] - Earnings per share (EPS) increased to $0.75, compared to $0.62 in Q3 2024, reflecting a 21% rise [1] Operational Highlights - Omnicell's gross margin improved to 55% in Q3 2025, up from 52% in Q3 2024, showcasing enhanced operational efficiency [1] - The company expanded its customer base by 10%, adding several new healthcare facilities to its portfolio [1] - Investments in technology and automation contributed to a 25% increase in productivity within its operations [1]